Hybio Pharmaceutical 翰宇药业
16 significant filings since 29 May 2026: 12 on equity incentive, 2 on guarantee or financial assistance and 1 on earnings pre-announcement, and 1 other kind. The latest, on 21 Aug 2026: 关于2026年度向金融机构申请综合授信及担保额度的进展公告. On 11 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 54.67% to 68.42% from the same period a year earlier.
自 29 May 2026 起有 16 份重大公告：equity incentive 12 份、guarantee or financial assistance 2 份、earnings pre-announcement 1 份，另有 1 类。最新一份（21 Aug 2026）：关于2026年度向金融机构申请综合授信及担保额度的进展公告。11 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 54.67% 至 68.42%。
As of 25 Sep 2026 截至2026年9月25日
Hybio Pharmaceutical, listed in 2011, operates in the chemical pharmaceuticals industry. The company reported a turnaround in 2025, posting a net profit of RMB36.6m compared to a loss of RMB173.7m in 2024, with revenue rising 63.7% to RMB966.4m. Profit quality was strong, as operating cash flow reached RMB0.26 per share, 6.87 times net profit. In the first half of 2026, profit grew 62.7% year-on-year to RMB236.7m, in line with its pre-announcement. However, financial risk is elevated: liabilities stood at 75.6% of assets as of 30 Jun 2026, and the current ratio was 0.46, indicating current liabilities exceed current assets. Recent filings show pledge releases by the controlling shareholders, but no new share pledges or liquidity warnings. The stock trades at high multiples, with a P/E of 161.0 and a price-to-book of 24.20x.
翰宇药业2011年上市，属于化学制药行业。公司2025年扭亏为盈，归母净利润3,657.0万元，2024年为-1.74亿元，营业收入同比+63.7%至9.66亿元。盈利质量良好，2025年每股经营现金流0.26元，为净利润的6.87倍。2026年上半年归母净利润同比+62.7%至2.37亿元，符合业绩预告。但财务风险较高，截至2026年6月30日资产负债率75.6%，流动比率0.46，显示流动负债超过流动资产。近期公告显示控股股东解除股份质押，无新增质押或流动性警示。股价估值偏高，市盈率（TTM）161.0，市净率24.20倍。
| Flag 标记 | Risk 风险 | Mechanism 影响机制 |
|---|---|---|
| Liabilities at 70% of assets or more 资产负债率达70%或以上 | Liabilities are high relative to assets. 负债占资产比例较高。 | At 75.6% of assets, liabilities indicate a leveraged capital structure that could limit financial flexibility. This level of indebtedness may increase refinancing risk, especially if operating cash flow weakens. 负债占资产75.6%，显示资本结构杠杆较高，可能限制财务灵活性。若经营现金流减弱，再融资风险可能上升。 |
| Current ratio below 1: current liabilities exceed current assets 流动比率低于1：流动负债超过流动资产 | Current liabilities exceed current assets. 流动负债超过流动资产。 | With a current ratio of 0.46, the company has fewer current assets than current liabilities, indicating potential short-term liquidity pressure. This could affect its ability to meet obligations without asset sales or external funding. 流动比率0.46，流动资产少于流动负债，显示短期偿债压力。若无资产处置或外部融资，可能影响偿债能力。 |
- Change in attributable net profit for the full year 2026 compared to 2025.
2026全年归母净利润相较2025年的变动。 - Liabilities to assets ratio as of 31 Dec 2026.
截至2026年12月31日的资产负债率。 - Operating cash flow per share for 2026.
2026年每股经营现金流。 - Any new share pledge or freeze filings by the controlling shareholders.
实际控制人是否有新增股份质押或冻结公告。 - Receivable days and inventory days as of 31 Dec 2026.
截至2026年12月31日的应收账款周转天数和存货周转天数。 - Revenue growth for the full year 2026 compared to 2025.
2026全年营业收入相较2025年的增长情况。
- Company: Hybio Pharmaceutical 翰宇药业, Shenzhen Stock Exchange 300199; industry Chemical Pharmaceuticals; listed 7 Apr 2011.
公司：翰宇药业，深圳证券交易所 300199；行业：化学制药；上市日期：2011年4月7日。 - Close on 24 Sep 2026 RMB23.30; close on 24 Sep 2025 RMB23.50; one-year change -0.9%.
2026年9月24日收盘价23.30元；2025年9月24日收盘价23.50元；一年涨跌幅-0.9%。 - 52-week range RMB16.36 to RMB26.52.
52周区间16.36元至26.52元。 - In the last 12 months 7 trading days closed 9% or more above or below the day before (all days, not only this year). The 5 most recent of them: 13 May 2026 +14.2%; 26 Jun 2026 -10.1%; 29 Jun 2026 +11.8%; 17 Jul 2026 -12.4%; 27 Jul 2026 +9.7%. The longest run of them on consecutive trading days: 2 days.
近12个月共有7个交易日收盘涨跌幅达9%及以上（为全部交易日，不限于今年）。其中最近5个：2026年5月13日 +14.2%；2026年6月26日 -10.1%；2026年6月29日 +11.8%；2026年7月17日 -12.4%；2026年7月27日 +9.7%。其中最长连续2个交易日。 - Market capitalisation RMB20.58bn; P/E TTM 161.0; price to book 24.20x.
总市值205.80亿元；市盈率（TTM）161.0；市净率24.20倍。 - Revenue 2025 RMB966.4m; 2024 RMB590.2m; change +63.7%.
营业收入2025年9.66亿元；2024年5.90亿元；同比+63.7%。 - Attributable net profit 2025 RMB36.6m; 2024 -RMB173.7m; change +121.1% (from a loss to a profit).
归属于母公司股东的净利润2025年3,657.0万元；2024年-1.74亿元；同比+121.1%（扭亏为盈）。 - Net profit excluding non-recurring items, 2025 change +105.8%.
2025年扣除非经常性损益后的净利润同比+105.8%。 - Basic EPS 2025 RMB0.04; 2024 -RMB0.20.
基本每股收益2025年0.04元；2024年-0.20元。 - Operating cash flow per share 2025 RMB0.26; 2024 RMB0.19; operating cash flow to net profit 6.87x.
每股经营现金流2025年0.26元；2024年0.19元；经营现金流与净利润之比6.87倍。 - 2025 gross margin 58.4%; net margin 3.5%; ROE 6.1%.
2025年毛利率58.4%；净利率3.5%；净资产收益率6.1%。 - At 30 Jun 2026: liabilities to assets 75.6%; current ratio 0.46; quick ratio 0.21; receivable days 35; inventory days 234.
截至2026年6月30日：资产负债率75.6%；流动比率0.46；速动比率0.21；应收账款周转天数35；存货周转天数234。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB688.3m, change +25.3%; attributable net profit RMB236.7m, change +62.7%; operating cash flow per share RMB0.35.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入6.88亿元，同比+25.3%；归母净利润2.37亿元，同比+62.7%；每股经营现金流0.35元。 - Pre-announcement of 11 Jul 2026 for the period to 30 Jun 2026: attributable net profit change +55% to +68%.
2026年7月11日发布的截至2026年6月30日业绩预告：归母净利润同比+55%至+68%。 - In the 12 months to 25 Sep 2026: 2 distinct filings classed critical, high or as a lift; by class: 2 filings classed Pledge Released. One filing can fall in more than one class, and several filings can concern one matter, such as the notice and the result of one auction.
截至2026年9月25日的近12个月：被归为重大、较高级别或解除类的公告共2份；按类别：归为解除质押的公告2份。同一公告可属多个类别，同一事项亦可有多份公告，例如同一拍卖的提示公告与结果公告。 - 27 Jun 2026, Pledge Released (medium): filing titled 《关于控股股东、实际控制人办理股票解除质押业务的公告》.
2026年6月27日，解除质押：公告《关于控股股东、实际控制人办理股票解除质押业务的公告》。 - 16 Apr 2026, Pledge Released (medium): filing titled 《关于控股股东、实际控制人办理部分股票质押暨解除质押业务的公告》.
2026年4月16日，解除质押：公告《关于控股股东、实际控制人办理部分股票质押暨解除质押业务的公告》。 - Ownership: actual controller 曾少贵,曾少强,曾少彬; largest holder at 30 Jun 2026: 曾少贵, 11.16%.
股权：实际控制人：曾少贵,曾少强,曾少彬；2026年6月30日第一大股东：曾少贵，持股11.16%。 - No distribution is held in this database, which begins on 1 Jan 2026; earlier distributions are not shown.
本数据库自2026年1月1日起记录，其中无该公司的分配记录；此前的分配未予显示。 - Aurelian Grade C, score 66.5 of 100, graded within a peer group of 158 companies in its industry; no rank among peers is given.
金源评级C，得分66.5（满分100），于行业同业158家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。